JF
KNSA icon

Jump Financial’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Jump Financial’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-39,735
Closed -$1.91M – 2262
2026
Q1 		$1.91M Sell
39,735
-51,694
-57% -$2.29M 0.03% 669
2025
Q4 		$3.77M Sell
91,429
-21,506
-19% -$863K 0.05% 451
2025
Q3 		$4.39M Sell
112,935
-113,103
-50% -$3.67M 0.05% 448
2025
Q2 		$6.25M Buy
+226,038
New +$5.75M 0.07% 355
2025
Q1 		– Sell
-14,601
Closed -$289K – 1822
2024
Q4 		$289K Sell
14,601
-31,006
-68% -$708K 0.01% 1319
2024
Q3 		$1.14M Buy
45,607
+34,444
+309% +$839K 0.02% 741
2024
Q2 		$208K Sell
11,163
-38,915
-78% -$729K ﹤0.01% 1551
2024
Q1 		$988K Sell
50,078
-4,142
-8% -$80.9K 0.03% 809
2023
Q4 		$951K Buy
+54,220
New +$891K 0.03% 750
2022
Q4 		– Sell
-19,400
Closed -$249K – 1825
2022
Q3 		$249K Sell
19,400
-4,419
-19% -$50.3K 0.01% 1244
2022
Q2 		$231K Buy
+23,819
New +$222K 0.01% 1208

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Jump Financial's KNSA Position: Q2 2026 in Review

Jump Financial sold out of Kiniksa Pharmaceuticals (KNSA) in Q2 2026, closing a stake of 39,735 shares — an estimated $1.91M sold.

Jump Financial first reported a position in KNSA in Q2 2022 and held it in 11 quarters. The position peaked at $6.25M in Q2 2025. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • Jump Financial reported no remaining Kiniksa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Jump Financial sold 39,735 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $1.91M.
  • Jump Financial first reported a position in Kiniksa Pharmaceuticals in Q2 2022 and held it in 11 quarters.
  • Jump Financial's Kiniksa Pharmaceuticals position peaked at $6.25M in Q2 2025.
  • 266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Jump Financial's 13F filing for Q2 2026, filed 13 Aug 2026.